Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health (NASDAQ:JAGX) is attending the Pet Connect conference from December 3-5, 2024, seeking partnerships for NP300, their novel prescription drug candidate for treating general, non-infectious diarrhea in dogs. NP300 shares similar mechanisms with Canalevia-CA1, their FDA conditionally approved drug for chemotherapy-induced diarrhea in dogs. The company estimates 6 million annual cases of acute and chronic diarrhea in U.S. veterinary visits. Despite diarrhea being one of the most common reasons for veterinary visits and the second most common cause for emergency room visits, there are currently no FDA-approved drugs for general canine diarrhea. The drug is derived from the Croton lechleri tree and has demonstrated safety in dogs.
Jaguar Health (NASDAQ:JAGX) parteciperà alla conferenza Pet Connect dal 3 al 5 dicembre 2024, alla ricerca di partnership per NP300, il loro nuovo candidato farmaceutico per il trattamento della diarrea non infettiva e generale nei cani. NP300 condivide meccanismi simili con Canalevia-CA1, il loro farmaco approvato condizionatamente dalla FDA per la diarrea indotta da chemioterapia nei cani. L’azienda stima 6 milioni di casi annuali di diarrea acuta e cronica nelle visite veterinarie negli Stati Uniti. Nonostante la diarrea sia uno dei motivi più comuni per le visite veterinarie e la seconda causa più comune di visite al pronto soccorso, attualmente non esistono farmaci approvati dalla FDA per la diarrea canina generale. Il farmaco è derivato dall'albero Croton lechleri e ha dimostrato sicurezza nei cani.
Jaguar Health (NASDAQ:JAGX) asistirá a la conferencia Pet Connect del 3 al 5 de diciembre de 2024, buscando asociaciones para NP300, su nuevo candidato a fármaco recetado para tratar la diarrea general y no infecciosa en perros. NP300 comparte mecanismos similares con Canalevia-CA1, su fármaco aprobado condicionalmente por la FDA para la diarrea inducida por quimioterapia en perros. La compañía estima 6 millones de casos anuales de diarrea aguda y crónica en visitas veterinarias en EE. UU. A pesar de que la diarrea es una de las razones más comunes para las visitas al veterinario y la segunda causa más común de visitas a la sala de emergencias, actualmente no hay medicamentos aprobados por la FDA para la diarrea canina general. El fármaco se deriva del árbol Croton lechleri y ha demostrado ser seguro en perros.
재규어 헬스 (NASDAQ:JAGX)는 2024년 12월 3일부터 5일까지 열리는 펫 커넥트 컨퍼런스에 참석하여 개의 일반 비감염성 설사를 치료하기 위한 새로운 처방약 후보인 NP300에 대한 파트너십을 모색합니다. NP300은 개의 화학요법 유발 설사를 위한 FDA의 조건부 승인 약물인 Canalevia-CA1과 유사한 메커니즘을 공유합니다. 이 회사는 미국 수의사 방문에서 600만 건의 연간 사례의 급성 및 만성 설사를 추정합니다. 설사는 수의사 방문의 가장 흔한 이유 중 하나이며 응급실 방문의 두 번째로 흔한 원인이지만, 현재 일반 개 설사를 위한 FDA 승인 약물은 없습니다. 이 약물은 Croton lechleri 나무에서 유래되었으며, 개에서 안전성을 입증했습니다.
Jaguar Health (NASDAQ:JAGX) assistera à la conférence Pet Connect du 3 au 5 décembre 2024, recherchant des partenariats pour NP300, leur nouveau candidat médicament sur ordonnance pour le traitement de la diarrhée générale non infectieuse chez les chiens. NP300 partage des mécanismes similaires avec Canalevia-CA1, leur médicament approuvé par la FDA sous condition pour la diarrhée induite par chimiothérapie chez les chiens. L'entreprise estime 6 millions de cas annuels de diarrhée aiguë et chronique lors de visites vétérinaires aux États-Unis. Bien que la diarrhée soit l'un des motifs les plus courants de visites chez le vétérinaire et la deuxième cause la plus fréquente de visites aux urgences, il n'existe actuellement aucun médicament approuvé par la FDA pour la diarrhée canine générale. Le médicament est dérivé de l'arbre Croton lechleri et a démontré sa sécurité chez les chiens.
Jaguar Health (NASDAQ:JAGX) wird vom 3. bis 5. Dezember 2024 an der Pet Connect-Konferenz teilnehmen und sucht Partnerschaften für NP300, ihren neuartigen verschreibungspflichtigen Medikamentenkandidat zur Behandlung von allgemeinem, nicht-infektiösen Durchfall bei Hunden. NP300 weist ähnliche Mechanismen wie Canalevia-CA1 auf, ihr von der FDA bedingt genehmigtes Medikament gegen durch Chemotherapie induzierten Durchfall bei Hunden. Das Unternehmen schätzt 6 Millionen jährliche Fälle von akutem und chronischem Durchfall in veterinärmedizinischen Besuchen in den USA. Trotz der Tatsache, dass Durchfall einer der häufigsten Gründe für veterinärmedizinische Besuche und die zweithäufigste Ursache für Notaufnahmen ist, gibt es derzeit keine von der FDA zugelassenen Medikamente gegen allgemeinen Hundedurchfall. Das Medikament wird aus dem Baum Croton lechleri gewonnen und hat sich als sicher bei Hunden erwiesen.
- Company has existing FDA conditionally approved drug Canalevia-CA1 for chemotherapy-induced diarrhea in dogs
- Large market potential with estimated 6 million annual cases of canine diarrhea in US
- NP300 has already demonstrated safety in dogs
- No current FDA-approved competition for general canine diarrhea treatment
- Company needs external partnership for funding and development of NP300
- Will need to give up US commercial rights to secure development partner
Insights
This development represents a significant market opportunity in the underserved veterinary pharmaceutical space. With 89.7 million dogs in the US and approximately 6 million annual cases of canine diarrhea seen by veterinarians, NP300 could potentially capture a substantial market share in a currently untapped segment. The lack of FDA-approved treatments for general canine diarrhea creates a first-mover advantage opportunity.
The strategic decision to seek partnerships rather than self-develop indicates a capital-efficient approach. The company's existing success with Canalevia-CA1 for chemotherapy-induced diarrhea provides validation for their antisecretory drug technology platform. However, the primary challenge lies in securing a well-resourced partner willing to fund development and commercialization in exchange for US commercial rights.
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA
SAN FRANCISCO, CA / ACCESSWIRE / December 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today issued a reminder that company personnel are attending the Pet Connect conference, taking place December 3-5, 2024 in Los Angeles, and are available for partnership discussions at the event. Jaguar is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S.
NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia®-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.
"We look forward to evaluating NP300 for treatment of general, non-infectious diarrhea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhea in dogs as well. We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs. We are attending the Pet Connect conference with the goal of speaking with potential partners about NP300."
Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the December 3-5, 2024 Pet Connect conference, and Jaguar's expectation that it may identify a partner organization to fund and execute development and commercialization of NP300. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What is Jaguar Health's (JAGX) new drug candidate NP300 designed to treat?
How many cases of canine diarrhea do US veterinarians see annually according to Jaguar Health (JAGX)?
What is Jaguar Health's (JAGX) currently approved drug for dogs?
What is Jaguar Health (JAGX) seeking at the December 2024 Pet Connect conference?
